skip to Main Content
Treating Patients
Like Individuals®
Precision Dosing Made Easier.
About Baysient® Schedule a Demo

Who is Baysient?

Baysient creates cloud-based software to facilitate individualized dosing of anti-inflammatory MAbs to improve outcomes in patients with inflammatory diseases like IBD. Baysient’s software utilizes a pioneering Compuceutical approach with Bayesian models, routine lab results and demographic information to allow physicians to individualize dosing to a specific target trough level.

read more

Why Baysient?

QUICK, SIMPLE AND EASY-TO-USE DOSAGE CALCULATOR
EFFORTLESS SETUP SO SIMPLE YOU’LL BE LIVE IN MINUTES
SAVE TIME AND REQUIRE LESS DRUG LEVELS
TAKE OUT THE GUESSWORK, CALCULATE A PRECISE MODEL-INFORMED DOSE IN SECONDS

Introducing

An integrative, cloud-based software that facilitates individualized dosing of all marketed MAbs used to treat a wide range of inflammatory diseases.

read more

How Does It Work?

Schedule a Demo

Interested in how iDose can improve your patient outcomes?

Diane R. Mould, PhD

Chief Science Officer, Baysient LLC

Dr. Diane R. Mould, Chief Scientific Officer (CSO) of Baysient, discusses individual variability in infliximab excretion and elimination. The variations seen in the individual pharmacokinetics of biologics highlight the need for more prospective data to further support effective personalized dosing. By focusing on important, modifiable factors for regulating drug levels, we can improve the efficacy of inflammatory disease treatments in clinical settings.

Latest Blog Post

precision-dosing-in-ibd-transforming-treatment-with-therapeutic-drug-monitoring

Precision Dosing in IBD: Transforming Treatment with Therapeutic Drug Monitoring

Inflammatory Bowel Disease (IBD) presents a significant treatment challenge for gastroenterologists worldwide. While biologic therapies have emerged as a cornerstone in managing these complex gastrointestinal conditions, their effectiveness is often hampered by a crucial factor – the variable clearance of biologic drugs from the patient’s…

Read More
Back To Top